George Nduva

Mr. George Nduva

Lund University
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Virus Evolution
Verified
Journal Article
Open access
PDF file
GNGeorge Nduva
George Nduva
FOFrederick Otieno
Frederick Otieno
JKJoshua Kimani
Joshua Kimani
EWElizabeth Wahome
Elizabeth Wahome
LMLyle R McKinnon
Lyle R McKinnon
JEJoakim Esbjörnsson
Joakim Esbjörnsson
In Kenya, HIV-1 key populations including men having sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW) are thought to significantly contribute to HIV-1 transmission in the wider, mostly heterosexual (HET) HIV-1 transmission network. However, clear data on HIV-1 transmission dynamics within and between these groups are limited. We aimed to empirically quantify rates of HIV-1 flow between key populations and the HET population, as well as between different geographic regions to determine HIV-1 ‘hotspots’ and their contribution to HIV-1 transmission in Kenya. We used maximum-likelihood phylogenetic and Bayesian inference to analyse 4058 HIV-1 pol sequences (representing 0.3 per cent of the epidemic in Kenya) sampled 1986–2019 from individuals of different risk groups and regions in Kenya. We found 89 per cent within-risk group transmission and 11 per cent mixing between risk groups, cyclic HIV-1 exchange between adjoining geographic provinces and strong evidence of HIV-1 dissemination from (i) West-to-East (i.e. higher-to-lower HIV-1 prevalence regions), and (ii) heterosexual-to-key populations. Low HIV-1 prevalence regions and key populations are sinks rather than major sources of HIV-1 transmission in Kenya. Targeting key populations in Kenya needs to occur concurrently with strengthening interventions in the general epidemic.

18 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAmin Hassan
Amin Hassan
JEJoakim Esbjörnsson
Joakim Esbjörnsson
EWElizabeth Wahome
Elizabeth Wahome
ATAlexander Thiong'O
Alexander Thiong'O
GNGeorge Nduva
George Nduva
ESEduard J Sanders
Eduard J Sanders
HIV-1 molecular epidemiology amongst men who have sex with men (MSM) in sub-Saharan Africa remains not well characterized. We aimed to determine HIV-1 subtype distribution, transmission clusters and transmitted drug resistance (TDR) in acute and early infected MSM from Coastal Kenya. Analysis of HIV-1 partial pol sequences from MSM recruited 2005–2017 and sampled within six months of the estimated date of infection. Volunteers were classified as men who have sex with men exclusively (MSME) or with both men and women (MSMW). HIV-1 subtype and transmission clusters were determined by maximum-likelihood phylogenetics. TDR mutations were determined using the Stanford HIV drug resistance database. Of the 97 volunteers, majority (69%) were MSMW; 74%, 16%, 9% and 1% had HIV-1 subtypes A1, D, C or G, respectively. Overall, 65% formed transmission clusters, with substantial mixing between MSME and MSMW. Majority of volunteer sequences were either not linked to any reference sequence (56%) or clustered exclusively with sequences of Kenyan origin (19%). Eight (8% [95% CI: 4–16]) had at least one TDR mutation against nucleoside (n = 2 [2%]) and/or non-nucleoside (n = 7 [7%]) reverse transcriptase inhibitors. The most prevalent TDR mutation was K103N (n = 5), with sequences forming transmission clusters of two and three taxa each. There were no significant differences in HIV-1 subtype distribution and TDR between MSME and MSMW. This HIV-1 MSM epidemic was predominantly sub-subtype A1, of Kenyan origin, with many transmission clusters and having intermediate level of TDR. Targeted HIV-1 prevention, early identification and care interventions are warranted to break the transmission cycle amongst MSM from Coastal Kenya.

19 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
GNGeorge Nduva
George Nduva
JNJamirah Nazziwa
Jamirah Nazziwa
AHAmin Hassan
Amin Hassan
ESEduard J. Sanders
Eduard J. Sanders
JEJoakim Esbjörnsson
Joakim Esbjörnsson
To reduce global HIV-1 incidence, there is a need to understand and disentangle HIV-1 transmission dynamics and to determine the geographic areas and populations that act as hubs or drivers of HIV-1 spread. In Sub-Saharan Africa (sSA), the region with the highest HIV-1 burden, information about such transmission dynamics is sparse. Phylogenetic inference is a powerful method for the study of HIV-1 transmission networks and source attribution. In this review, we assessed available phylogenetic data on mixing between HIV-1 hotspots (geographic areas and populations with high HIV-1 incidence and prevalence) and areas or populations with lower HIV-1 burden in sSA. We searched PubMed and identified and reviewed 64 studies on HIV-1 transmission dynamics within and between risk groups and geographic locations in sSA (published 1995–2021). We describe HIV-1 transmission from both a geographic and a risk group perspective in sSA. Finally, we discuss the challenges facing phylogenetic inference in mixed epidemics in sSA and offer our perspectives and potential solutions to the identified challenges.

21 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GNGeorge Nduva
George Nduva
AHAmin S. Hassan
Amin S. Hassan
JNJamirah Nazziwa
Jamirah Nazziwa
SGSusan M. Graham
Susan M. Graham
JEJoakim Esbjörnsson
Joakim Esbjörnsson
ESEduard J. Sanders
Eduard J. Sanders
HIV-1 transmission patterns within and between populations at different risk of HIV-1 acquisition in Kenya are not well understood. We investigated HIV-1 transmission networks in men who have sex with men (MSM), injecting drug users (IDU), female sex workers (FSW) and heterosexuals (HET) in coastal Kenya. We used maximum-likelihood and Bayesian phylogenetics to analyse new (N = 163) and previously published (N = 495) HIV-1 polymerase sequences collected during 2005–2019. Of the 658 sequences, 131 (20%) were from MSM, 58 (9%) IDU, 109 (17%) FSW, and 360 (55%) HET. Overall, 206 (31%) sequences formed 61 clusters. Most clusters (85%) consisted of sequences from the same risk group, suggesting frequent within-group transmission. The remaining clusters were mixed between HET/MSM (7%), HET/FSW (5%), and MSM/FSW (3%) sequences. One large IDU-exclusive cluster was found, indicating an independent sub-epidemic among this group. Phylodynamic analysis of this cluster revealed a steady increase in HIV-1 infections among IDU since the estimated origin of the cluster in 1987. Our results suggest mixing between high-risk groups and heterosexual populations and could be relevant for the development of targeted HIV-1 prevention programmes in coastal Kenya.

1 March 2026
Verified
Journal Article
Open access
ESErik Sörstedt
Erik Sörstedt
GNGeorge Nduva
George Nduva
FMFredrik Månsson
Fredrik Månsson
ÅMÅsa Mellgren
Åsa Mellgren
JRJohanna Repits
Johanna Repits
CCChristina Carlander
Christina Carlander
HIV guidelines recommend switching from a three-drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long-term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline-recommended 3DR between July 2019 and May 2023 in routine clinical care. Demographic and clinical data were obtained from InfCareHIV at baseline, 6, 12, 24, 36 and 42 months post-switch. The primary endpoint was virologic failure (VF) rates at each time point; secondary endpoints included VF rates in prespecified subgroups, time to VF, and incidence of viral blips and treatment-emergent resistance. Generalized estimating equations modelling was used to assess the effects of clinical predictors on VF. A total of 1125 individuals (46%) switched to DTG+3TC, and 1336 (54%) switched to 3DR. Adjusted VF rates post-switch were 0.1-2.9% in the DTG+3TC group and 0.3-2.2% in the 3DR group in the intent-to-treat analysis (0-0.4% and 0.3-2.3% in the on-treatment [OT] analysis, respectively). In the OT set, the odds of VF were significantly lower for DTG+3TC versus 3DR at 24, 36 and 42 months (p<0.001). Treatment-emergent resistance rates were low in both groups. In this long-term, real-world, national cohort, switching to DTG+3TC was associated with low rates of VF and antiretroviral therapy resistance, indicating that eligible individuals can be switched to DTG+3TC without increased risk of VF.

26 February 2026 in Journal of the International AIDS Society
Verified
Journal Article
Open access
ESErik Sörstedt
Erik Sörstedt
GNGeorge Nduva
George Nduva
FMFredrik Månsson
Fredrik Månsson
ÅMÅsa Mellgren
Åsa Mellgren
JRJohanna Repits
Johanna Repits
CCChristina Carlander
Christina Carlander
Introduction: HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended 3DR between July 2019 and May 2023 in routine clinical care. Methods: Demographic and clinical data were obtained from InfCareHIV at baseline, 6, 12, 24, 36 and 42 months post‐switch. The primary endpoint was virologic failure (VF) rates at each time point; secondary endpoints included VF rates in prespecified subgroups, time to VF, and incidence of viral blips and treatment‐emergent resistance. Generalized estimating equations modelling was used to assess the effects of clinical predictors on VF. Results: A total of 1125 individuals (46%) switched to DTG+3TC, and 1336 (54%) switched to 3DR. Adjusted VF rates post‐switch were 0.1–2.9% in the DTG+3TC group and 0.3–2.2% in the 3DR group in the intent‐to‐treat analysis (0–0.4% and 0.3–2.3% in the on‐treatment [OT] analysis, respectively). In the OT set, the odds of VF were significantly lower for DTG+3TC versus 3DR at 24, 36 and 42 months ( p <0.001). Treatment‐emergent resistance rates were low in both groups. Conclusions: In this long‐term, real‐world, national cohort, switching to DTG+3TC was associated with low rates of VF and antiretroviral therapy resistance, indicating that eligible individuals can be switched to DTG+3TC without increased risk of VF.